Compare KNSL & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KNSL | PODD |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 10.2B |
| IPO Year | 2016 | 2007 |
| Metric | KNSL | PODD |
|---|---|---|
| Price | $399.36 | $133.84 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 26 |
| Target Price | ★ $354.56 | $177.91 |
| AVG Volume (30 Days) | 244.4K | ★ 1.2M |
| Earning Date | 10-22-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.25% | N/A |
| EPS Growth | ★ 21.77 | N/A |
| EPS | ★ 16.97 | 4.69 |
| Revenue | $1,873,987,000.00 | ★ $2,708,100,000.00 |
| Revenue This Year | $3.76 | $22.02 |
| Revenue Next Year | N/A | $11.70 |
| P/E Ratio | ★ $23.31 | $29.27 |
| Revenue Growth | 18.04 | ★ 30.73 |
| 52 Week Low | $287.20 | $126.40 |
| 52 Week High | $421.90 | $342.13 |
| Indicator | KNSL | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 61.15 | 36.46 |
| Support Level | $349.06 | $128.80 |
| Resistance Level | $405.41 | $150.04 |
| Average True Range (ATR) | 10.80 | 8.12 |
| MACD | 0.01 | -2.36 |
| Stochastic Oscillator | 77.88 | 2.78 |
Kinsale Capital Group Inc is an insurance holding company. The company is engaged in offering property, casualty, and specialty insurance products. It offers specialty insurance products for allied health, healthcare, life sciences, professional, and a public entity. The company operates in only one reportable segment which is the Excess and Surplus Lines Insurance segment, which includes commercial excess and surplus lines liability and property insurance products through its underwriting divisions. The company generates revenues in the form of premiums and investment income.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.